MaxCyte

MaxCyte, Inc. (MXCT) reported a solid start to the fiscal year 2024, with total revenue reaching $11.3 million in the first quarter. The company’s financial health appears robust, with a combined total of $202.5 million in cash, cash equivalents, and investments, and no debt reported at the end of Q1.…